This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.
The trial results showed that patients receiving Keytruda demonstrated an objective response rate of 46%. ... an objective response rate of 46% for certain patients with advanced endometrial carcinoma … treated with Keytruda.”.
with Keytruda, which supplemented standard chemotherapy prior to surgery, with a follow-up treatment using Keytruda after surgery. ... After their surgery, patients continued to receive either Keytruda without chemotherapy, or placebo.
The study evaluated the combination of Lenvima plus Keytruda versus chemotherapy for patients diagnosed with advanced, metastatic, or recurrent endometrial carcinoma. ... The results presented demonstrated that the combination of Lenvima plus Keytruda
Keytruda’s first approval seven years ago was also in melanoma, said Dr Scot Ebbinghaus from Merck Research Laboratories. ... Since then, we have built on this foundation in melanoma and have expanded the use of Keytruda into earlier stages of this
While patients whose tumours express PD-L1 can receive immunotherapies like Merck/MSD’s Keytruda (pembrolizumab), advanced TNBC remains a very difficult cancer to treat.
Merck’s anti-PD-1 therapy, Keytruda, is approved in the Europe Union for certain patients with triple-negative breast cancer plus chemotherapy. ... Patients in all 27 European Union member states plus Iceland, Lichtenstein, Norway and Northern Ireland
More from news
Approximately 174 fully matching, plus 283 partially matching documents found.
Merck Sharp &Dohme (MSD), the company that markets Keytruda, and Bristol-Myers Squibb (BMS), the company that markets Opdivo, approached development of their respective products in this area with starkly contrasting
Opdivo is being squeezed out of the market by Merck &Co/ MSD’s Keytruda (pembrolizumab), which dominates the lucrative first-line NSCLC market and is cutting into BMS’ share of the ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor
its role in developing immuno-oncology blockbuster Keytruda. ... The coming Keytruda windfall will also allow the charity to set up a stand-alone venture capital division, with which it could seed funding and help promote research in key areas.
The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the
PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.
More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.
Under his leadership, Merck has seen impressive growth for its immunotherapy blockbuster Keytruda (pembrolizumab) and other innovative treatments.
This includes the approval of Merck’s checkpoint inhibitor Keytruda (pembrolizumab), which has been approved in over 25 indications across 16 tumour types. ... Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations,
The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck &Co's Keytruda.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
OncoSec’s intratumoral IL-12 EP platform not only enhances anti–PD-(L) 1 activity (currently treating anti-PD-1–refractory melanoma patients with pembrolizumab [Keytruda] plus its investigational TAVO in
Last year the FDA made a pioneering move in this space and approved Keytruda for use in adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or
Here’s a look at Keytruda, the drug Jimmy Carter says made his tumors vanish.
However, hidden in the pipeline was the ‘miracle’ immuno-oncology drug Keytruda.
Impressively, Opdivo consistently outperformed Merck &Co.'s ($MRK) Keytruda (pembrolizumab), racking up $1.58 billion in sales during the first half of 2016 compared to $563 million earned by its main ... Rubbing salt into BMS’s wounds, Merck's
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...